The Road Ahead: Special Research on Dillard's, Toll Brothers, Chegg, First Solar, and Biocept

NEW YORK, February 25, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.  

Moments ago, Analysts Review released new research updates concerning several important developing situations including Dillard's (NYSE: DDS), Toll Brothers (NYSE: TOL), Chegg (NYSE: CHGG), First Solar (NASDAQ: FSLR), and Biocept (NASDAQ: BIOC). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

DDS Research Report: ( http://get.analystsreview.com/pdf/?c=Dillard%27s&d=25-Feb-2015&s=DDS ),

TOL Research Report: ( http://get.analystsreview.com/pdf/?c=Toll%20Brothers&d=25-Feb-2015&s=TOL ),

CHGG Research Report: ( http://get.analystsreview.com/pdf/?c=Chegg&d=25-Feb-2015&s=CHGG ),

FSLR Research Report: ( http://get.analystsreview.com/pdf/?c=First%20Solar&d=25-Feb-2015&s=FSLR ),

BIOC Research Report: ( http://get.analystsreview.com/pdf/?c=Biocept&d=25-Feb-2015&s=BIOC ).

============

--

Analyst Update: Strong Results, New Agreement, Positive Results of Study

Reviewed by: Rohit Tuli, CFA®  

US stocks rose to record levels on Tuesday after Federal Reserve Chair Janet Yellen suggested that the central bank is not likely to begin raising interest rates for at least the next couple monetary policy meetings; and intends a rate hike only when they are "reasonably confident" that annual inflation is moving back toward their 2 percent target. The S&P 500 gained 5.82 points, or 0.28%, to end at 2,115.48, and the Dow Jones Industrial Average edged up 92.35 points or 0.51% to 18,209.19. The tech-heavy NASDAQ advanced for the tenth straight session, up 7.15 points or 0.14% to close at 4,968.12. Meanwhile, most of Europe's benchmark stock indices closed higher on Tuesday, following reports that Eurozone finance ministers, the European Commission, the European Central Bank and the International Monetary Fund have approved Greece's request for an extended €240 billion ($273 billion) bailout. Germany's DAX 30 rose 0.67% to 11,205.74, while, FTSE 100 gained 0.54% to 6,949.63. France's CAC 40 gained 0.50% to 4,886.44.

Shares in Dillard's, Inc. (Dillard's) were up 2.64% on the last close as the Company finished 2014 with its best sales performance of the year in the fourth quarter, with a 3% increase in comparable store sales and a 103 basis point retail gross margin improvement. To continue reading on the quarterly performance of the leading fashion apparel, cosmetics and home furnishings retailer, visit our research report on Dillard's.

Toll Brothers Inc's (Toll Brothers) stock rallied 3.85% on the last close, led by the strong first quarter 2015 results reported by the Company. The luxury home builder's net income for the period rose 78% YoY, driven by higher home sales and prices. To know how the results compared with the analysts' expectations and Company's updated guidance for fiscal 2015, read our research report on Toll Brothers.

Shares of Chegg, Inc. (Chegg) opened 14.4% higher at $7.70 in morning market trading Tuesday after the textbook company beat analysts' estimates for earnings in Q4 and announced a new agreement with Ingram Content Group. The shares hit a new 52-week high of $8.71, before closing up 27.41% at $8.60. Chegg reported earnings of 19 cents a share, beating analysts' estimates of 15 cents a share for the quarter, as reported by Thestreet.com. Read more about the financial performance and the new agreement struck between Ingram and Chegg in our research report.

Shares of First Solar, Inc. (First Solar) ended Tuesday's trading at $54.70, up 10.19% following reports that Q4 2014 net income of the Company increased almost three-fold to $192.0 million on YoY basis. Q4 2014 Earnings per share also surpassed analyst estimates, while reported revenue were below consensus estimates. Know more about First Solar's fourth quarter and full year financial results in our research report.

Shares of Biocept, Inc. (Biocept) surged 54.09% on Monday to end the session at $3.39 after the Company announced that its blood-based diagnostic, OncoCEE-BR™, was used to determine hormonal status of metastatic breast cancer patients in a prospective study performed at the Columbia University College of Physicians and Surgeons in New York City. Read more about the Company's achievement in our research report.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review